Regeneron Pharmaceuticals, Inc. REGN | NASDAQ
Next Earnings: Jul 24, 2026
Company Overview:
10 Year REGN Performance Metrics:
REGN Dividend Payments, Yield & Share Price charts
Unlock All Reports & Research Dividend Stocks.
[lev_ptables no_sale]REGN Dividend Safety: Payout & Dividend to Free Cash Flow Ratios.
REGN Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
REGN Dividends Info:
REGN Dividend History: Dates, Payments & Yield list
Below is a schedule of all REGN dividend payments, ex-dates, share price on the day of the payment as well as TTM & forward yield
| Ex-Date | Payment Date | Amount | TTM Yield | Forward Yield | Price on Ex-Date |
|---|---|---|---|---|---|
| 05/20/2026 | 06/04/2026 | $0.940 | 0.56% | 0.6% | $628.73 |
| 02/20/2026 | 03/05/2026 | $0.940 | 0.46% | 0.49% | $764.93 |
| 11/20/2025 | 12/05/2025 | $0.880 | 0.48% | 0.49% | $718.36 |
| 08/18/2025 | 09/03/2025 | $0.880 | 0.46% | 0.62% | $563.80 |
| 05/20/2025 | 06/06/2025 | $0.880 | 0.29% | 0.71% | $493.22 |
| 02/20/2025 | 03/20/2025 | $0.880 | 0.13% | 0.53% | $662.62 |
Projected Future Returns & Dividends for REGN
Based on past 10-year performance, here are REGN growth metrics:
Share price CAGR of +5.24%
Dividend CAGR of +5.61%
Using REGN CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| REGN (DRIP) | REGN - No DRIP | |
|---|---|---|
| Current Price | $651.91 | $651.91 |
| Start Shares | 15.34 | 15.34 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 16.26 | 15.34 |
| Dividends Payment | $1.62 | $1.62 |
| Annual Dividends | $106 | $100 |
| Yield on cost | 1.06% | 1.00% |
| Share Price | $1,085.98 | $1,085.98 |
| Total Dividends | $770 | $747 |
| Final Value | $17,663 | $17,405 |
NOTE: Above numbers are our estimate based on REGN's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
[lev_ptables no_sale]Company Info
Regeneron Pharmaceuticals, Inc. (REGN) had its IPO on 1991-04-02, and is trader on NASDAQ stock exchange.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
REGN website: https://www.regeneron.com
